🟢 Summit Therapeutics is trading 5% up today with no clear company-specific catalyst

Summit Therapeutics is trading at $15.64, up 5.18%, with no clearly identified company-specific announcement explaining the August 11, 2026 advance.

• The latest notable company news was the August 5 HARMONi-GU1 bladder-cancer study announcement; an August 6 fiduciary-duty investigation was also reported. Neither directly explains today’s gain.
• Broader markets are mixed: the S&P 500 is up 0.05% and Nasdaq is down 0.21%. Positioning around ivonescimab and its November 14 FDA decision may be a factor, but remains unconfirmed.